Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMY) is dated May 1, 2019. The report addresses Item 8.01 (Other Events) regarding the early tender results of exchange offers and consent solicitations related to Celgene Corporation notes, in connection with Bristol-Myers Squibb's planned acquisition of Celgene.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only specific financial figure disclosed relates to the debt exchange offer:
- Exchange Offer Amount: Up to $19,850,000,000 aggregate principal amount of new notes issued by Bristol-Myers Squibb and cash.
Material Changes
The primary material event reported is the successful receipt of the requisite number of consents to adopt amendments to the Celgene Indentures. These amendments eliminate substantially all restrictive covenants and certain events of default. Celgene has executed supplemental indentures to implement these changes. This action is a condition precedent to the closing of the Merger.
Guidance, Outlook, and Risks
- Merger Timeline: The closing of the Merger is expected to occur in the third quarter of calendar year 2019.
- Offer Expiration: The Exchange Offers and Consent Solicitations are set to expire on June 3, 2019, unless extended or terminated earlier.
- Conditions: The offers are conditioned upon the closing of the Merger. The amendments will only become operative upon the settlement of the Exchange Offers.
- Extension Possibility: Bristol-Myers Squibb anticipates providing notice of any extension to the expiration date in advance.
Investor Verification Checklist
- Verify the final settlement of the Exchange Offers to confirm the amendments become operative.
- Monitor the Merger closing date to ensure it aligns with the third-quarter 2019 expectation.
- Check for any announcements regarding the extension of the June 3, 2019 expiration date.
- Review the attached press release (Exhibit 99.1) for additional details on the exchange terms.